APPLICATION PROCEDURES FOR THERAPEUTIC USE EXEMPTIONS (TUE) If a player needs a medical treatment requiring the use of a prohibited substance (as defined in the List of the WADA Prohibited Substances and Methods) and if there is no therapeutic alternative, s/he must apply for a Therapeutic Use Exemption (TUE). Only TUE applications for players intending to participate in competitions of FIBA (as defined under article E.1 of the FIBA Internal Regulations governing the Competitions of FIBA) or in competitions of the Euroleague Basketball or EuroCup, or in the Olympic Games are to be addressed to FIBA (regardless of whether the Player previously has received a TUE at national level). TUE applications will be studied by at least three doctors who are member of the FIBA TUE Committee (TUEC) and sent back to the applicant with an approval or refusal. I. USE OF INHALED BETA-2 AGONISTS (for asthma or one of its clinical variants) A player who intends to use inhaled Terbutaline must submit a TUE and a full medical file in advance of participating in a FIBA Competition. The medical file shall include the following pulmonary function tests: A spirometry with flow/volume loop after administration of a placebo and of a beta 2 mimetic agent. If this test is inconclusive, a provocation test must be used. These tests must be performed under the supervision of a specialist in pneumology (or allergology), in a qualified laboratory. A simple prescription for medication from a doctor is not considered as providing adequate proof. The FIBA TUE Committee highly recommends a yearly follow up by a specialist with the WADA’s recommended evaluation tests. B. Salbutamol – Salmeterol - Formoterol: These medications are not forbidden at the indicated values: Salbutamol (maximum 1600 micrograms over 24 hours), Formoterol (maximum 36 micrograms over 24 hours) and salmeterol when taken by inhalation in accordance with the manufacturers’ recommended therapeutic regime. The presence in urine of salbutamol in excess of 1000 ng/mL or Formoterol in excess of 30 ng/mL is presumed not to be an intended therapeutic use of the substance and will be considered as an Adverse Analytical Finding unless the player proves, through a controlled pharmacokinetic study, that the abnormal result was the consequence of the use of the therapeutic inhaled dose up to the maximum indicated above. Please refer to the bottom of this document. (Note 3) Only This FIBA original Document is considered as admissible II. USE OF GLUCOCORTICOSTEROIDS (GCS) The type of documentation to be submitted for the use of Glucocorticosteroids (GCS) depends on the route of administration (how the medication is administered or taken). Prohibited Route Systemic administration: : A full TUE application must be submitted if GCS are taken by the following routes: Orally (through the mouth, usually in the form of pills or tablets) Intravenous injection (injected into a vein) Intramuscular injection (injected straight into a muscle) Rectally (into the rectum usually in the form of a suppository or rectal application of a All the other routes are not prohibited. III. PLATELET-DERIVED PREPARATIONS (e.g.: Platelet rich plasma, “Blood spinning”) Such methods require neither longer Declaration of Use nor TUE Application. The use of any other substance or method included in the Prohibited List requires a completed TUE application form together with a complete medical file to be submitted. The Prohibited List can be downloaded by clicking here. Note: For the use of amphetamine in case of ADHD (Attention Deficit Hyperactivity Disorder), a complete medical file must be provided containing the treatments during childhood, the current treatment and psychiatric examination. V. SUBMISSION REQUIREMENTS TUE applications and medical reports must be filled in a LEGIBLE way, in either English or French (although results of tests may be in the original language), using the FIBA forms (click here) and must be addressed to FIBA as soon as possible and in any event (save in emergency situations) no later than 30 days before the first day of a FIBA Competition. Players who are or were included in the FIBA Registered Testing Pools (RTP1 & RTP2) may submit their TUE applications directly via ADAMS. Such RTP Players who do not have access to ADAMS can request an ADAMS user account from tue@fiba.com Only This FIBA original Document is considered as admissible If all of the required information is attached to the player’s submission in ADAMS, there is no need to print off the file and send it signed to FIBA. Players having an ADAMS user account can download the ADAMS TUE User Guide by clicking here. • Applications by the following means: 53, avenue Louis-Casaï P.O. Box 110 1216 Cointrin / Geneva SWITZERLAND The FIBA TUE Rules are available under article 4.4 of the FIBA Internal Regulations governing Anti-Doping and are in line with the WADA World Anti-Doping Code and the WADA International Standard for TUEs. Abbreviated TUEs granted by FIBA before 2009 have all expired on 31 December 2009 (as per art. 11.1 of the WADA International Standards for TUEs). After that date, new TUE applications must be submitted as described in the above guidelines. There are no longer substances or methods on the Prohibited List that require a Declaration of Use and therefore it is not necessary to file a Declaration of Use. However, the player should still write all the medications and substances taken in the last seven days on the Doping Control Form, at the time of testing. Only This FIBA original Document is considered as admissible

Source: http://www.czechrepublic2010.fiba.com/downloads/v3_expe/medi/2012_TUE_application_procedure.pdf


T H E M E N D E R Z E I T Ernst Gräfenberg Wer (er)fand den G-Punkt? Medizinhistorische Anmerkungen zur Erstbeschreibung vor 61 Jahren Matthias David, Frank C. K. Chen, Jan-Peter Siedentopf Ernst Gräfenberg: Ende der 20er-Jahre hatte er eine erfolgreiche Praxis in lungen“ für die temporäre Sterilität ver-Selten fand ein medizinischer Fach- nach Berlin,wo er sich als Gynäkol

English abstracts.doc

Bulletin of Clinical and Experimental Endocrinology MS-02 Insulin Resistance in the Development of Metabolic Syndrome in Females with Abnormalities in Reproductive Sphere R.M.Mamedgasanov, G.R.Fatalieva, S.S.Safarova, S.E.Meshadieva Azerbaijan Medical University, Baku, Azerbaijan Backgrounds and aims: The aim of present investigation was the relation of hyperandrogenem

Copyright © 2010-2019 Pdf Physician Treatment